생체이용률 향상 기술 및 서비스 시장 : 약제 클래스별, BCS 분류 유형별, 생체이용률 향상 접근 유형별, 제형별, 주요 지역별 - 업계 동향과 세계 예측(- 2035년)

Bioavailability Enhancement Technologies and Services Market by Type of Drug Class, Type of BCS Classification, Type of Bioavailability Enhancement Approach, Type of Dosage Form, Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,778,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,886,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,971,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,423,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 생체 이용률 향상 기술 및 서비스 시장 규모는 2035년까지 예측 기간 동안 11.11%의 연평균 복합 성장률(CAGR)로 확대되어 현재 32억 달러에서 2035년 10억 2,000만 달러로 성장할 것으로 예상됩니다.

최근 몇 년동안 약물의 수용성 문제가 증가함에 따라 의약품 개발자의 초점은 친 유성 약물 화합물 개발로 옮겨 가고 있습니다. 최근 연구에 따르면 NCE의 약 90%가 BCS 클래스 II 및 IV에 속하며, 이는 낮은 투과성과 관련이 있는 것으로 알려져 있습니다. 낮은 생체 이용률로 인해 많은 의약품이 시장에 출시되지 않는 것을 감안할 때 업계는이 문제를 완화하기 위해 다양한 도구/방법을 모색하고 있습니다. 또한, 많은 기업들이 생체 이용률이 낮은 기존 제품 후보를 재처방하기 위해 노력하고 있기 때문에 새로운 생체 이용률 향상 방법에 대한 수요가 크게 증가하고 있습니다.

2000년 이후 55개 이상의 바이오 이용률 향상 기술 및 서비스를 제공하는 기업이 설립되었습니다는 점은 주목할 만합니다. 경쟁이 치열해지면서 최첨단 도구와 기술을 이용할 수 있다는 점이 차별화 요소로 부상했습니다. 이에 따라 많은 서비스/기술 제공업체들이 전략적 인수/합병 또는 다른 바이오의약품 가용성 향상 기업과의 서비스 제휴를 통해 적극적으로 포트폴리오를 확장하고 있습니다. 제약 개발자들이 새로운 약물 타겟과 클래스를 계속 평가함에 따라, 바이오베버리지 개선 분야는 향후 10년간 꾸준히 성장할 것으로 예상됩니다.

아웃소싱은 약물의 생체 이용률 향상을 위한 인기 있는 모델로 등장하고 있으며, 약 115개 업체가 다양한 생체 이용률 향상 원칙에 따라 다양한 서비스를 제공합니다.

현재 80% 이상의 기업이 주로 고체 분산 접근법을 사용하여 약물의 용해도 개선에 중점을 둔 생체이용률 향상 서비스를 제공합니다. 생체이용률 향상 기술의 발전으로 약동학적 특성이 개선된 새로운 제제 개발이 가능해지면서 기술 제공업체에게 유리한 기회가 생기고 있습니다. 기술의 50% 이상이 소분자, 특히 경구 투여를 목적으로 하는 분자의 생체이용률을 높이는 데 초점을 맞추었습니다.

지난 10년간 다양한 지역에서 생체이용률을 개선한 새로운 치료 중재를 평가하기 위한 여러 임상시험이 등록되었습니다. 다양한 생체이용률 향상 기술을 다룬 5,800여 편의 논문이 다양한 과학 저널에 게재되어 이 분야의 연구 활동이 빠르게 발전하고 있음을 알 수 있습니다. 생체 이용률 향상 분야는 광범위한 연구개발 활동이 특징이며, 이는 여러 고부가가치 기술과 강력한 지적재산권 포트폴리오의 개발로 이어지고 있습니다. 시장이 꾸준히 발전하는 가운데, 스타트업은 혁신적인 생체 이용률 향상 기술을 도입하여 서비스 포트폴리오를 확장하고 경쟁에서 우위를 점하기 위해 노력해야 합니다.

세계의 생체이용률 향상 기술 및 서비스 시장에 대해 조사했으며, 시장 개요와 함께 약물 유형별, BCS 분류 유형별, 생체이용률 향상 접근법 유형별, 제형별, 주요 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 서론

제4장 시장 구도 : 생체이용률 향상 서비스 제공업체

제5장 시장 구도 : 생체이용률 향상 기술 제공업체

제6장 주요 인사이트

제7장 기업 개요

• 본 장의 개요
• Adare Pharma Solutions
• Ascendia Pharmaceuticals
• Catalent
• Formulex Pharma Innovations(formerly SoluBest)
• Lonza
• Lubrizol Life Science Health
• Pace Analytical
• Quotient Sciences
• WuXi STA(A Subsidiary of WuXi AppTec)

제8장 기업 벤치마킹 분석

제9장 파트너십 및 협업

제10장 출판물 분석

제11장 특허 분석

제12장 임상시험 분석

제13장 기술 평가 프레임워크

제14장 수요 분석

제15장 시장 예측과 기회 분석

제16장 결론

제17장 부록 I : 기업 리스트

제18장 부록 II : 표 데이터

LSH

영문 목차

영문목차

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: OVERVIEW

As per Roots Analysis, the global bioavailability enhancement technologies and services market is estimated to grow from USD 3.2 billion in the current year to USD 10.22 billion by 2035, at a CAGR of 11.11% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Drug Class

• New Drug Approvals
• Generics

Type of BCS Classification

• BCS II Drugs
• BCS IV Drugs

Type of Bioavailability Enhancement Approach

• Solid Dispersion
• Size Reduction
• Lipid-based
• Other Approaches

Type of Dosage Form

• Liquids
• Solids
• Semi-Solids
• Fine Particles

Key Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa
• Rest of the World

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: GROWTH AND TRENDS

In recent years, the focus of drug developers has shifted towards development of lipophilic drug compounds due to the increasing issues with aqueous solubility of drugs. According to a recent study, around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability, the demand for novel bioavailability enhancement methods has grown significantly.

It is worth mentioning that since 2000, more than 55 players offering bioavailability enhancement technologies and services have been established. Amidst the growing competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor. This has led many service / technology providers to actively expand their portfolios, either through strategic acquisitions / mergers or entering into service alliances with other bioavailability enhancement companies. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace over the next decade.

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY INSIGHTS

The report delves into the current state of the bioavailability enhancement technologies and services market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Outsourcing has emerged as a popular model for improving drug bioavailability, with nearly 115 companies offering a wide range of services based on different bioavailability enhancement principles.

• At present, more than 80% of the players are offering bioavailability enhancement services focused on improving the drug solubility, primarily by adopting the solid dispersion approach.
• Advances in bioavailability enhancement technologies have enabled the development of novel formulations with improved pharmacokinetic properties, resulting in lucrative business opportunities for technology providers.
• Over 50% of the technologies are focused on enhancing the bioavailability of small molecules, specifically those intended for delivery via the oral route.
• A rise in partnerships focused on bioavailability enhancement services and technology platforms validates the growing interest in this domain; ~40% of such deals were instances of mergers and acquisitions.
• In the past decade, several clinical trials have been registered for evaluating novel therapeutic interventions with improved bioavailability, across different geographical regions.
• 5,800+ articles discussing various bioavailability enhancement techniques have been published in different scientific journals, thereby indicating the rapid pace of research activity within this domain.
• Bioavailability enhancement domain is characterized by extensive R&D activity, leading to the development of multiple high value technologies and a strong intellectual property portfolio.
• With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition.
• Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future.
• Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035.

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: KEY SEGMENTS

New Drug Approvals Occupy the Largest Share of the Bioavailability Enhancement Technologies and Services Market

Based on the type of drug class, the market is segmented into new drug approvals and generics. At present, new drug approvals hold the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the near future.

BCS II Drug Class is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of BCS classification, the market is segmented into BCS II drugs and BCS IV drugs. Currently, BCS II drug class holds the maximum share of the bioavailability enhancement technologies and services market. This trend is likely to remain the same in the coming decade.

Size Reduction Approach is the Fastest Growing Segment of the Bioavailability Enhancement Technologies and Services Market During the Forecast Period

Based on the type of bioavailability enhancement approach, the market is segmented into solid dispersion, size reduction, lipid-based and other approaches. It is worth highlighting that, lipid-based approach holds a larger share of the bioavailability enhancement technologies and services market. However, the bioavailability enhancement technologies and services market for size reduction approach is likely to grow at a relatively higher CAGR.

Liquid Dosage Form is Likely to Dominate the Bioavailability Enhancement Technologies and Services Market

Based on the type of dosage form, the market is segmented into liquids, solids, semi-solids and fine particles dosage form. Currently, liquid dosage form holds the maximum share of the bioavailability enhancement technologies and services market. This trend is unlikely to change in the foreseeable future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, Latin America, and Rest of the World. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia is expected to grow at a higher CAGR.

Example Players in the Bioavailability Enhancement Technologies and Services Market

• Adare Pharma Solutions
• Ascendia Pharmaceuticals
• Catalent
• Lonza
• Lubrizol Life Science Health
• Pace Life Sciences
• Quotient Sciences
• WuXi STA

BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the bioavailability enhancement technologies and services market, focusing on key market segments, including [A] type of drug class, [B] type of BCS classification, [C] type of bioavailability enhancement approach, [D] type of dosage form, and [J] key geographical regions.
• Market Landscape 1: A comprehensive evaluation of bioavailability enhancement service providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] bioavailability enhancement principle supported, [E] bioavailability enhancement approach employed, [F] type of dosage form supported, and [G] route of administration of drug product.
• Market Landscape 2: A comprehensive evaluation of bioavailability enhancement technology providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of employee count), [C] location of headquarters, [D] bioavailability enhancement principle supported, [E] bioavailability enhancement approach employed, [F] type of molecule, [G] type of dosage form supported, [H] route of administration, [I] availability for license and [J] associated intellectual property rights.
• Key Insights: A detailed analysis, encompassing the contemporary market trends, using six schematic representations, including [A] a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, [B] a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them, [C] a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, [D] a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, [E] an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered), as well as [F] a 3D bubble analysis comparing the key players engaged in drug bioavailability enhancement market, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).
• Company Profiles: In-depth profiles of key industry players offering bioavailability enhancement technologies and services, focusing on [A] company overviews, [B] financial information (if available), [C] bioavailability enhancement services portfolio, [D] recent developments and [E] an informed future outlook.
• Competitive Benchmarking Analysis: A competitive benchmarking analysis that emphasizes the primary focus areas of various players engaged in the drug bioavailability enhancement market. This analysis compares their existing capabilities within and beyond their respective peer groups based in North America, Europe, Asia-Pacific, and other regions. It offers stakeholders insights into potential strategies for achieving a competitive edge in the industry.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2013, covering mergers and acquisitions, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements.
• Publication Analysis: A detailed review of peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as [A] year of publication, [B] type of publication, [C] popular keywords, [D] top journals, [E] top publishers and [F] top copyright holders (in terms of number of articles published).
• Patent Analysis: Detailed analysis of various patents filed / granted related to bioavailability enhancement approaches and technologies based on [A] type of patent, [B] patent application year, [C] patent publication year, [D] bioavailability enhancement approach, [E] CPC symbols, [F] geography, [G] emerging focus area, [H] type of organization, [I] leading industry and non-industry players (in terms of number of patents filed/granted), and [J] individual patent assignees (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various bioavailability enhancement of various drug compounds and / or candidates based on parameters like [A] trial registration year, [B] trial phase, [C] current recruitment status, [D] enrolled patient population, [E] study design, [F] type of sponsor / collaborator, [G] leading industry and non-industry players (in terms of number of registered trials conducted), [H] type of molecule and [I] key geographies.
• Technology Evaluation Framework: An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Scope of the Report
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Key Questions Answered
• 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. Historical Evolution of Bioavailability Enhancement Technologies
• 3.3. Assessment of Drug Bioavailability
  • 3.3.1. Key Considerations for Bioavailability and Assessment Studies
    • 3.3.1.1. Absolute Bioavailability
    • 3.3.1.2. Relative Bioavailability
    • 3.3.1.3. Single and Multiple Dose Studies
  • 3.3.2. Studies in Healthy Subjects and Patients
    • 3.3.2.1. Different Bioavailability Assessment methods
• 3.4. Need for Bioavailability Enhancement
• 3.5. Factors Affecting Bioavailability
  • 3.5.1. Drug Related Factors
  • 3.5.2. Patient Physiology Related Factors
• 3.6. Bioavailability Enhancement Technologies
  • 3.6.1. Physical Technologies for Bioavailability Enhancement
    • 3.6.1.1. Solid Dispersion
      • 3.6.1.1.1. Classification of Solid Dispersion Approaches
      • 3.6.1.1.2. Methodologies for Solid Dispersion Approaches
        • 3.6.1.1.2.1. Hot Melt Extrusion
        • 3.6.1.1.2.2. Melting / Fusion Methods
        • 3.6.1.1.2.3. Solvent Evaporation
        • 3.6.1.1.2.4. Spray-Dried Dispersion
        • 3.6.1.1.2.5. Other Techniques Used for Solid Dispersion
    • 3.6.1.2. Nanosuspension Technology
      • 3.6.1.2.1. Top-Down Approach
      • 3.6.1.2.2. Bottom-Up Approach
  • 3.6.2. Chemical Technologies for Bioavailability Enhancement
    • 3.6.2.1. Lipid-Based Formulations
    • 3.6.2.2. Non-Metal-Based Drug Delivery Systems
    • 3.6.2.3. Polymer-Based Drug Delivery Systems
  • 3.6.3. Biological Technologies for Bioavailability Enhancement
• 3.7. Concluding remarks

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS

• 4.1. Chapter Overview
• 4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Bioavailability Enhancement Principle
  • 4.2.5. Analysis by Bioavailability Enhancement Approach
    • 4.2.5.1. Analysis by Solid Dispersion Approaches
    • 4.2.5.2. Analysis by Size Reduction Approaches
    • 4.2.5.3. Analysis by Lipid-Based Approaches
    • 4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
  • 4.2.6. Analysis by Dosage Form
  • 4.2.7. Analysis by Route of Administration

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS

• 5.1. Chapter Overview
• 5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
  • 5.2.1. Analysis by Year of Establishment
  • 5.2.2. Analysis by Company Size
  • 5.2.3. Analysis by Location of Headquarters
  • 5.2.4. Analysis by Company Size and Location of Headquarters
  • 5.2.5. Leading Players: Analysis by Number of Technologies
• 5.3. Bioavailability Enhancement Technologies: Market Landscape
  • 5.3.1. Analysis by Bioavailability Enhancement Principle
  • 5.3.2. Analysis by Bioavailability Enhancement Approach
  • 5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
  • 5.3.4. Analysis by Type of Molecule
  • 5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
  • 5.3.6. Analysis by Dosage Form
  • 5.3.7. Analysis by Route of Administration
  • 5.3.8. Analysis by Availability for License
  • 5.3.9. Analysis by Intellectual Property Rights

6. KEY INSIGHTS

• 6.1. Chapter Overview
  • 6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
  • 6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
  • 6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
  • 6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
  • 6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
  • 6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)

7. COMPANY PROFILES

• 7.1. Chapter Overview
• 7.2. Adare Pharma Solutions
  • 7.2.1. Company Overview
  • 7.2.2. Financial Overview
  • 7.2.3. Recent Developments and Future Outlook
• 7.3. Ascendia Pharmaceuticals
  • 7.3.1. Company Overview
  • 7.3.2. Financial Overview
  • 7.3.3. Recent Developments and Future Outlook
• 7.4. Catalent
  • 7.4.1. Company Overview
  • 7.4.2. Financial Overview
  • 7.4.3. Recent Developments and Future Outlook
• 7.5. Formulex Pharma Innovations (formerly SoluBest)
  • 7.5.1. Company Overview
  • 7.5.2. Financial Overview
  • 7.5.3. Recent Developments and Future Outlook
• 7.6. Lonza
  • 7.6.1. Company Overview
  • 7.6.2. Financial Overview
  • 7.6.3. Recent Developments and Future Outlook
• 7.7. Lubrizol Life Science Health
  • 7.7.1. Company Overview
  • 7.7.2. Financial Overview
  • 7.7.3. Recent Developments and Future Outlook
• 7.8. Pace Analytical
  • 7.8.1. Company Overview
  • 7.8.2. Financial Overview
  • 7.8.3. Recent Developments and Future Outlook
• 7.9. Quotient Sciences
  • 7.9.1. Company Overview
  • 7.9.2. Financial Overview
  • 7.9.3. Recent Developments and Future Outlook
• 7.10. WuXi STA (A Subsidiary of WuXi AppTec)
  • 7.10.1. Company Overview
  • 7.10.2. Financial Overview
  • 7.10.3. Recent Developments and Future Outlook

8. COMPANY BENCHMARK ANALYSIS

• 8.1. Chapter Overview
• 8.2. Company Benchmarking Analysis: Methodology
• 8.3. Company Benchmarking Analysis: Peer Groups
  • 8.3.1. Benchmarking of Players based in North America, Established Pre 2000 (Peer Group I)
  • 8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
  • 8.3.3. Benchmarking of Players based in North America, Established Post 2010 (Peer Group III)
  • 8.3.4. Benchmarking of Players based in Europe, Established Pre 2000 (Peer Group IV)
  • 8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
  • 8.3.6. Benchmarking of Players based in Europe, Established Post 2010 (Peer Group VI)
  • 8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre 2000 (Peer Group VII)
  • 8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post 2000 (Peer Group VIII)

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. Bioavailability Enhancement: Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Year and Type of Partnership
  • 9.3.4. Analysis by Type of Partner
  • 9.3.5. Analysis by Type of Partnership and Type of Partner
  • 9.3.6. Most Active Players: Analysis by Number of Partnerships
• 9.4. Analysis by Geography
  • 9.4.1. Analysis by Region
  • 9.4.2. Analysis by Country
  • 9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters

10. PUBLICATION ANALYSIS

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. Bioavailability Enhancement: Publication Analysis
  • 10.3.1. Analysis by Year of Publication
  • 10.3.2. Analysis by Type of Publication
  • 10.3.3. Analysis by Bioavailability Enhancement Approach
  • 10.3.4. Analysis by Year of Publication and Bioavailability Enhancement Approach
  • 10.3.5. Most Popular Journals: Analysis by Number of Publications
  • 10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
  • 10.3.7. Most Popular Publishers: Analysis by Number of Publications
  • 10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
  • 10.3.9. Analysis by Popular Keywords

11. PATENT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Bioavailability Enhancement: Patent Analysis
  • 11.3.1. Analysis by Application Year
  • 11.3.2. Analysis by Publication Year
  • 11.3.3. Analysis by Bioavailability Enhancement Approach
  • 11.3.4. Analysis by CPC Symbols
  • 11.3.5. Analysis by Geography
  • 11.3.6. Analysis by Emerging Focus Areas
  • 11.3.7. Analysis by Type of Organization
  • 11.3.8. Leading Players: Analysis by Number of Patents
• 11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis
  • 11.4.1. Analysis by Patent Characteristics
• 11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
• 11.6. Leading Patents: Analysis by Number of Citations

12. CLINICAL TRIAL ANALYSIS

• 12.1. Chapter Overview
• 12.2. Guidelines To Conduct Bioavailability Studies
• 12.3. Bioavailability Enhancement: Clinical Trials Analysis
  • 12.3.1. Research Methodology
  • 12.3.2. Analysis of Trials by Trial Registration Year
  • 12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
  • 12.3.4. Analysis of Trials by Study Design
  • 12.3.5. Analysis of Trials by Trial Phase
  • 12.3.6. Analysis of Trials by Trial Recruitment Status
  • 12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
  • 12.3.8. Analysis by Type of Molecule and Trial Phase
  • 12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
  • 12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
  • 12.3.11. Analysis by Study Focus
  • 12.3.12. Analysis of Trials by Geography
  • 12.3.13. Analysis of Enrolled Patient Population by Geography

13. TECHNOLOGY EVALUATION FRAMEWORK

• 13.1. Chapter Overview
• 13.2. Key Assumptions and Methodology
• 13.3. Technologies based on Solid Dispersion Approaches
  • 13.3.1. List of Approved Drugs
  • 13.3.2. Trends in Intellectual Capital
  • 13.3.3. Trends in Research Activity
  • 13.3.4. Business Model Adopted by Developers
• 13.4. Technologies based on Size Reduction Approaches
  • 13.4.1. List of Approved Drugs
  • 13.4.2. Trends in Intellectual Property
  • 13.4.3. Trends in Research Activity
  • 13.4.4. Business Model Adopted by Developers
• 13.5. Technologies based on Lipid-based Approaches
  • 13.5.1 List of Approved Drugs
  • 13.5.2 Trends in Intellectual Property
  • 13.5.3. Trends in Research Activity
  • 13.5.4. Business Model Adopted by Developers
• 13.6. Technology Evaluation Framework: Wind Rose Representation
• 13.7. Results and Discussions

14. DEMAND ANALYSIS

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Methodology
• 14.3. Global Demand for Bioavailability Enhancement Technologies and Services, till 2035
• 14.4. Analysis by Drug Class, Current Year and 2035
  • 14.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, till 2035
  • 14.4.2. Demand for Bioavailability Enhancement Technologies and Services for Generics, till 2035
• 14.5. Analysis by BCS Classification, Current Year and 2035
  • 14.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, till 2035
  • 14.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, till 2035
• 14.6. Analysis by Dosage Form, Current Year and 2035
  • 14.6.1. Demand for Bioavailability Enhancement Technologies and Services for Liquids, till 2035
  • 14.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids, till 2035
  • 14.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi- Solids, till 2035
  • 14.6.4. Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, till 2035
  • 14.6.5. Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, till 2035
• 14.7. Concluding Remarks

15. MARKET FORECAST AND OPPURTUNITY ANALYSIS

• 15.1. Chapter Overview
• 15.2. Forecast Methodology and Key Assumptions
• 15.3. Global Bioavailability Enhancement Services Market, till 2035
• 15.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, Current

Year and 2035

• 15.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, till 2035
• 15.4.2. Bioavailability Enhancement Services Market for Generics, till 2035
• 15.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, Current Year and 2035
  • 15.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, till 2035
  • 15.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, till 2035
• 15.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, Current Year and 2035
  • 15.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches, till 2035
  • 15.6.2. Bioavailability Enhancement Services Market for Size Reduction Based Approaches, till 2035
  • 15.6.3. Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, till 2035
  • 15.6.4. Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, till 2035
• 15.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form,

Current Year and 2035

• 15.7.1. Bioavailability Enhancement Services Market for Liquids, till 2035
• 15.7.2. Bioavailability Enhancement Services Market for Solids, till 2035
• 15.7.3. Bioavailability Enhancement Services Market for Semi-Solids, till 2035
• 15.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders, till 2035
• 15.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, till 2035
• 15.8. Bioavailability Enhancement Services Market: Analysis by Key Geographies, Current Year and 2035
  • 15.8.1. Bioavailability Enhancement Services Market in North America, till 2035
  • 15.8.2. Bioavailability Enhancement Services Market in Europe, till 2035
  • 15.8.3. Bioavailability Enhancement Services Market in Asia, till 2035
  • 15.8.4. Bioavailability Enhancement Services Market in Latin America, till 2035
  • 15.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa, till 2035
  • 15.8.6. Bioavailability Enhancement Services Market in Rest of the World, till 2035
• 15.9. Concluding Remarks

16. CONCLUSION

17. APPENDIX I: LIST OF COMPANIES

18. APPENDIX II: TABULATED DATA

관련자료